Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 5von Hippel-Lindau Disease 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Hemangioblastoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1

Interventions

Nivolumab 11Specimen Handling 8Ipilimumab 7pembrolizumab 5CTLA-4 Antigen 5cabozantinib 4Magnetic Resonance Spectroscopy 4Biopsy 4Radiosurgery 3Axitinib 3pazopanib 2Sunitinib 2Everolimus 2Blood Specimen Collection 2tivozanib 1sodium-iodide symporter 1sitravatinib 1lenvatinib 1belzutifan 1aldesleukin 1Zoledronic Acid 1Tissue Banks 1Selenomethionine 1Radiotherapy 1Radiopharmaceuticals 1Nephrectomy 1Molecular Imaging 1Metastasectomy 1Inulin 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Clear-cell metastatic renal cell carcinoma × belzutifan × Clear all
NCT07179770 2025-09-23

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

NYU Langone Health

Phase 1 Recruiting
12 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡